Extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative diease

Phase 2

Completed

• Conditions: Post solid organ transplant lymphoproliferative disease; Other -

• Registration Number: ACTRN12607000190404
• Lead Sponsor: Alberto Fernández de Sevilla on behalf of the Catalan Institute of Oncology

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2007-04-02
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Signed informed consent, untreated B-cell lymphoproliferative disease, CD20 expression.

Exclusion Criteria

Central nervous system disease, serious concomitant diseases.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Complete remission rate[8 weeks after the end of the treatment (with CT scan). If there were clinical data suggesting progression, patients could be evaluated at 4 weeks after the end of treatment.]

Secondary Outcome Measures

Name	Time	Method
Overall response rate[At 8 weeks after the end of treatment. If there were clinical data suggesting progression patients could be evaluated at 4 weeks after the end of treatment. ];Overall survival and progression-free survival at 2 years after the end of treatment[At 2 years after the end of treatment.]